BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Money on the Move: April Showers Bring May Flowers—and Funding

  Dianthus Therapeutics, Enavate Sciences and CytoTronics were all launched with this recent wave of investor funding. For that and more, continue reading.

  May 4, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Novartis’ Kisqali Adds Years to Breast Cancer Patients’ Lives

  Novartis’ Kisqali (ribociclib) plus the chemotherapy drug fulvestrant provided some post-menopausal breast cancer patients’ survival benefit of more than five-and-a-half years of life.

  May 4, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Weigh to Go: Gelesis Boasts Positive Results for Weight Loss Treatment

  PureTech Health announced its founded entity, Gelesis Holdings, presented positive results from the Light-Up clinical trial of GS200 in overweight and obese adults who have prediabetes or type 2 diabetes.

  May 4, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Career Advice

  What You Need to Know Before Applying to a Small Pharma Company

  BioSpace spoke with Annick Deschoolmeester, Head of Human Resources at Pharvaris, about some of the ways she’s noticed small companies differ from large ones.

  May 4, 2022

   · 

  5 min read

   · 

  Kaley Lefevre
• 

  Drug Development

  Phathom Wins Approvals Against Antibiotic Resistance in H. pylori

  The FDA has approved two of Phathom Pharmaceuticals’ products for bacterial illnesses in adults: Voquezna Triple Pak and Voquezna Dual Pak.

  May 4, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform

  Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.

  May 4, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Athira Investor Calls For Former GSK Exec to Take Reigns

  Athira investor Richard Kayne appears to be making a strong push for Dr. Ronald Krall, former chief medical officer of GlaxoSmithKline, to run the company, despite protests from Athira’s board.

  May 4, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Following Q1 Assessment, Allogene Remains Focused on CAR-T Therapy

  After the market closed on Wednesday, Allogene reported its first-quarter financial results, along with updates to its research programs. The report marked Allogene’s fourth anniversary.

  May 4, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Connect Seeks Partners to Advance UC Asset after Phase II Fail

  Connect Biopharma Phase II trial on a potential drug for adults with moderate-to-severe ulcerative colitis may have failed to meet its primary endpoint, but the company isn’t giving up yet.

  May 4, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Moderna Highlights More than $6B in Revenue, Talks Boosters

  Moderna held its 2022 Q1 earnings call this morning announcing $6.1 billion in revenue and robust plans to roll out COVID-19 boosters this fall.

  May 4, 2022

   · 

  2 min read

   · 

  Hayley Shasteen